“Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty”

[1] Ford D(1998)Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium Am J Hum Genet 62 676-689

[2] Easton DF(2003)Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science (New York, NY) 302 643-646

[3] Stratton M(1997)The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 1401-1408

[4] King MC(2002)Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 1609-1615

[5] Marks JH(2006)Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation JAMA, J. Am. Med. Assoc. 296 185-192

[6] Mandell JB(2009)Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 80-87

[7] Struewing JP(2006)Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study Lancet Oncol 7 223-229

[8] Hartge P(2006)ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 24 4642-4660

[9] Wacholder S(2002)Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or −2 mutations. Implications for gross examination, cytology, and clinical follow-up Am J Surg Pathol 26 171-178

[10] Kauff ND(2002)Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy Gynecol Oncol 85 397-403

[1] Ford D(1998)Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium Am J Hum Genet 62 676-689

[2] Easton DF(2003)Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science (New York, NY) 302 643-646

[3] Stratton M(1997)The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 1401-1408

[4] King MC(2002)Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 1609-1615

[5] Marks JH(2006)Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation JAMA, J. Am. Med. Assoc. 296 185-192

[6] Mandell JB(2009)Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 80-87

[7] Struewing JP(2006)Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study Lancet Oncol 7 223-229

[8] Hartge P(2006)ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 24 4642-4660

[9] Wacholder S(2002)Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or −2 mutations. Implications for gross examination, cytology, and clinical follow-up Am J Surg Pathol 26 171-178

[10] Kauff ND(2002)Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy Gynecol Oncol 85 397-403